分化型甲状腺癌术后^(131)I联合利可君治疗的临床应用研究  

Clinical Application of Iodine-131 Radiotherapy Combined with Leucoge in Post-operated Patient with Differentiated Thyroid Cancer

作　　者：王荣福[1] 王飞[2] 李颖[2] 崔永刚[1] 赵媛[3] 吴茜[1] 

机构地区：[1]北京大学第一医院核医学科,北京100034 [2]北京大学第一医院药剂科,北京100034 [3]北京中医药大学东方医院核医学科,北京100078

出　　处：《标记免疫分析与临床》2014年第1期19-21,28,共4页Labeled Immunoassays and Clinical Medicine

基　　金：国家重大科学仪器设备开发专项(2011YQ03011409);国家自然科学基金(81071183);北京大学医学部医工建设项目(BMU20120297)

摘　　要：目的探讨分化型甲状腺癌[differentiated thyroid carcinoma,DTC]术后131I联合利可君治疗的可行性,以提高甲状腺癌患者接受治疗期间的依从性和疗效。方法回顾性分析2007年1月至2013年3月167例DTC术后残留、局部复发、淋巴结转移和/或全身转移的患者在接受131I治疗期间联合应用利可君治疗的效果。根据131I治疗前未给予利可君、131I治疗后给予利可君(20mg/次,tid)为A组47例;131I治疗前未给予利可君、131I治疗后给予利可君(40mg/次,tid)为B组57例;131I治疗前为预防WBC和PLT降低给予利可君(20mg/次,tid)、治疗后给予利可君(80mg/次,tid)为C组66例。结果131I治疗和联合利可君治疗DTC患者167例,A、B、C三组患者在样本量、年龄相近、131I治疗前WBC、PLT水平的差异均无统计学意义(P>0.05);3组患者131I治疗后的WBC和PLT呈不同程度的变化,其中A组和B组的WBC和PLT可见明显减少(P<0.05),C组未见明显变化(P>0.05);131I治疗分化型甲状腺癌术后残留、局部复发或远处转移的疗效可靠。结论分化型甲状腺癌术后131I治疗期间联合利可君治疗是预防WBC和PLT减少及骨髓抑制的有效方法。Objective To investigate the feasibility of combined 131I and Leucoge curing the differentiated thyroid carcinoma after operation and in order to enhance the therapeutic compliance and efficacy in the thyroid cancer patients during therapy period. Methods The information was collected and then had a retrospective analysis in 167 differentiated thyroid cancer patients with postoperative residual thyroid tissue, local recurrence or lymph node and systemic metastases. Total 167 patients were divided into 3 groups that was based on giving Leucogen tablets 20rag rid （Group A, n =47）, 40rag rid （Group B, n =54） and 80rag tid （Group C, n =66） following post-treatment with 131I. The therapeutic effectiveness of 131I combined with Leucoge was evaluated during therapy period. Results There were no change between three groups in sample size, age, WBC and PLT before curing of 131I （P 〉 0.05）. The level of WBC and PLT in three groups had selective change after 131I treatment. The WBC and PLT levels in Group A and Group B had significantly decreased （P 〈 0.05 ） and no effect in Group C （ P 〉 0.05 ）. The efficacy of 131I on differentiated thyroid carcinoma with postoperative residual thyroid tissue, local and distant metastases was confirmed in this study. Conclusion The combination of 131I andLeucoge is an effective cure on postoperative differentiated thyroid carcinoma to prevent the decrease of WBC and PLT as well as bone marrow suppression.

关 键 词：分化型甲状腺癌 放射性碘 利可君 

分 类 号：R736.1[医药卫生—肿瘤]